Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately assess, diagnose and manage medical conditions.
Rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial infection and non-bacterial etiology.
Rapid point-of-care test that simultaneously tests for acute respiratory infections caused by the COVID-19, Influenza A and Influenza B viruses.
Lumos specializes in rapid, cost-effective and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. We offer customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.
Initial evaluation of a point-of-care diagnostic test product concept and the development of new diagnostic test assay.
Development of new point-of-care diagnostic test products, including use of Lumos technology platform and the customization and integration of Lumos digital reader technology when requested by Lumos clients.
Clinical and product validation and commercial-scale manufacture of test strips and readers.
In house, qualified team to support all stages of product development and commercialization.
Learn more about the Australian roll-out of FebriDx
This device is now available via qualified clinicians to help patients more accurately navigate the need for antibiotics.
Lumos has announced a binding A$5.0 million secured loan facility with major shareholders, Tenmile and Ryder Capital.
Lumos has today announced a pivotal commercial development for its breakthrough diagnostic product, FebriDx®
Lumos held an investor briefing outlining the transformational US$317 million distribution agreement with PHASE Scientific.
By entering your email address you are agreeing to our Privacy Policy.
Innovation at the point-of-care
2024 Lumos Diagnostics
